Vericel (VCEL) Competitors $42.01 +0.78 (+1.89%) Closing price 04:00 PM EasternExtended Trading$42.01 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. ROIV, LNTH, TGTX, RVMD, BBIO, LEGN, BPMC, SRPT, TLX, and AXSMShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Legend Biotech Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Roivant Sciences (NASDAQ:ROIV) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership. Does the MarketBeat Community prefer ROIV or VCEL? Vericel received 301 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.26% of users gave Roivant Sciences an outperform vote while only 61.85% of users gave Vericel an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% VericelOutperform Votes35561.85% Underperform Votes21938.15% Which has more volatility & risk, ROIV or VCEL? Roivant Sciences has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Which has stronger earnings & valuation, ROIV or VCEL? Roivant Sciences has higher earnings, but lower revenue than Vericel. Roivant Sciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M58.56$4.35B-$0.15-67.07Vericel$237.22M8.88-$3.18M$0.18233.39 Do analysts recommend ROIV or VCEL? Roivant Sciences currently has a consensus target price of $17.50, indicating a potential upside of 73.96%. Vericel has a consensus target price of $60.86, indicating a potential upside of 44.86%. Given Roivant Sciences' higher probable upside, equities analysts plainly believe Roivant Sciences is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ROIV or VCEL? 64.8% of Roivant Sciences shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 5.2% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ROIV or VCEL more profitable? Vericel has a net margin of 1.56% compared to Roivant Sciences' net margin of -119.54%. Vericel's return on equity of 1.48% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Vericel 1.56%1.48%0.96% Does the media prefer ROIV or VCEL? In the previous week, Vericel had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 15 mentions for Vericel and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.26 beat Vericel's score of 0.79 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Vericel 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive SummaryVericel beats Roivant Sciences on 10 of the 18 factors compared between the two stocks. Remove Ads Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio700.2831.0021.7317.81Price / Sales8.88441.15379.1994.60Price / Cash3,081.95168.6838.1534.64Price / Book8.883.476.464.00Net Income-$3.18M-$72.06M$3.20B$247.23M7 Day Performance8.83%9.33%6.54%7.26%1 Month Performance-7.43%-16.97%-8.55%-6.26%1 Year Performance-13.74%-29.10%10.33%-0.18% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel2.4215 of 5 stars$42.01+1.9%$60.86+44.9%-13.9%$2.11B$237.22M700.28300News CoverageROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-6.9%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3411 of 5 stars$95.45+5.0%$129.43+35.6%+68.0%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3148 of 5 stars$37.25-0.3%$40.67+9.2%+171.3%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.816 of 5 stars$31.40+0.3%$65.23+107.7%+1.1%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.5716 of 5 stars$30.67-2.2%$52.64+71.6%+29.9%$5.83B$221.90M-10.76400Analyst ForecastGap DownLEGNLegend Biotech2.409 of 5 stars$30.25-5.5%$79.00+161.2%-39.3%$5.56B$627.24M-31.841,070Positive NewsGap UpBPMCBlueprint Medicines2.6248 of 5 stars$80.20-1.8%$124.95+55.8%-5.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6725 of 5 stars$52.40-3.7%$163.18+211.4%-55.5%$5.08B$1.90B41.92840Short Interest ↑High Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5823 of 5 stars$98.50-0.4%$169.80+72.4%+49.7%$4.80B$385.69M-16.44380Analyst Revision Remove Ads Related Companies and Tools Related Companies ROIV Competitors LNTH Competitors TGTX Competitors RVMD Competitors BBIO Competitors LEGN Competitors BPMC Competitors SRPT Competitors TLX Competitors AXSM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VCEL Stock Free VCEL Stock Alerts